info@seagull-health.com
SeagullHealth
search
Sofosbuvir/Velpatasvir/Voxilaprevir(Vosevi)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Vosevi(Sofosbuvir/Velpatasvir/Voxilaprevir) Instructions:Uses,Dosage, Side Effects
VOSEVI is a fixed-dose combination tablet containing three direct-acting antiviral agents: sofosbuvir, velpatasvir, and voxilaprevir. It is designed as a salvage therapy for adult patients with chronic hepatitis C virus (HCV) infection, targeting multiple viral proteins to inhibit replication.
The tablet is formulated for oral administration and is specifically indicated for patients who have prior treatment experience with certain HCV regimens, particularly those involving NS5A inhibitors or sofosbuvir without an NS5A inhibitor.
Genotype 1, 2, 3, 4, 5, or 6 infection in patients previously treated with an HCV regimen containing an NS5A inhibitor.
Genotype 1a or 3 infection in patients previously treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor.
One tablet taken orally once daily with food.
Treatment duration is 12 weeks.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
